Cero Therapeutics Holdings Inc. held special shareholder meeting

Cero Therapeutics Holdings Inc. held a special shareholder meeting on December 19, 2025, where stockholders approved amendments to authorize a reverse stock split and increase shares in the 2024 Equity Incentive Plan.

Cero Therapeutics Advances Phase 1 Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings Inc. has provided an update on its Phase 1 trial of CER-1236 for acute myeloid leukemia (AML). The trial has completed the dose-limiting toxicity observation for the second cohort's first patient at a higher dose. A second patient in the first cohort received an additional dose. The study aims to evaluate the safety and preliminary efficacy of CER-1236. Enrollment and dosing are ongoing with continued safety monitoring.

Cero Therapeutics Holdings Inc - Continues To Evaluate Additional Options For Up-List

Dec 2 (Reuters) - CERo Therapeutics Holdings Inc (CERO.PK) :* CERO THERAPEUTICS HOLDINGS INC - CONTINUES TO EVALUATE ADDITIONAL OPTIONS FOR UP-LIST Source text: Further company coverage: (CERO.PK)

Cero Therapeutics Announces $14.6 Million Private Stock Sale to Institutional Investor

Cero Therapeutics Holdings Inc. has announced a private stock sale agreement with an institutional investor to issue and sell up to $14.6 million of its common stock. This agreement continues the company's previous equity line arrangements. The sales will be made in a private placement without registration under the Securities Act, with each transaction capped at 10,000 shares or $100,000.

CERo Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0